Share on StockTwits

NxStage Medical (NASDAQ:NXTM) President Joseph E. Turk, Jr. unloaded 1,500 shares of NxStage Medical stock on the open market in a transaction dated Thursday, June 5th. The stock was sold at an average price of $14.00, for a total transaction of $21,000.00. Following the sale, the president now directly owns 129,447 shares of the company’s stock, valued at approximately $1,812,258. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $16.83.

Shares of NxStage Medical (NASDAQ:NXTM) opened at 13.75 on Wednesday. NxStage Medical has a one year low of $8.77 and a one year high of $15.00. The stock has a 50-day moving average of $12.77 and a 200-day moving average of $12.36. The company’s market cap is $844.5 million.

NxStage Medical (NASDAQ:NXTM) last released its earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. The company had revenue of $72.20 million for the quarter, compared to the consensus estimate of $69.44 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. Analysts expect that NxStage Medical will post $-0.40 EPS for the current fiscal year.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.